{
  "url": "https://struct.news/briefs/treasury-bonds-oil-and-biotech-are-moving-together",
  "title": "Treasury bonds, oil and biotech are moving together",
  "summary": "Ten active names span seven sectors, from SHY and USO to Apogee and Diamondback, despite barely tracking one another normally.",
  "published_at": "2026-08-12T23:47:43.063985+00:00",
  "publisher": "Struct",
  "usage": "Figures are as reported by the company. Quote with attribution to the source filing.",
  "company": {
    "name": null,
    "ticker": null,
    "cik": null,
    "sector": null,
    "industry": null
  },
  "source_filing": null,
  "comparison_filing": null,
  "reported_figures": [
    {
      "group": "A cross-sector group moving unusually closely",
      "label": "Recent correlation",
      "value": 0.7951,
      "display": "0.80",
      "unit": "number",
      "period": null,
      "detail": null,
      "source": {
        "kind": "jodie_evidence",
        "label": "Broad-market moves removed",
        "as_of": "2026-08-12"
      }
    },
    {
      "group": "A cross-sector group moving unusually closely",
      "label": "Usual correlation",
      "value": 0.0003,
      "display": "0.00",
      "unit": "number",
      "period": null,
      "detail": null,
      "source": {
        "kind": "jodie_evidence",
        "label": "Broad-market moves removed",
        "as_of": "2026-08-12"
      }
    },
    {
      "group": "A cross-sector group moving unusually closely",
      "label": "Above normal",
      "value": 4.42,
      "display": "4.4σ",
      "unit": "sigma",
      "period": null,
      "detail": null,
      "source": {
        "kind": "jodie_evidence",
        "label": "Broad-market moves removed",
        "as_of": "2026-08-12"
      }
    }
  ],
  "watch_next": [
    {
      "type": "product_pipeline",
      "statement": "Zumilokibart spending increased as the APEX Phase 2 trial generated higher clinical-trial costs.",
      "importance": "medium",
      "evidence": "Research and development expense related to the zumilokibart program increased by $3.6 million in the three months ended June 30, 2026, compared to the three months ended June 30, 2025, primarily driven by an increase in clinical trial-related expenses associated with our APEX Phase 2 clinical trial.",
      "source_date": "2026-08-10"
    },
    {
      "type": "product_pipeline",
      "statement": "Zumilokibart-related R&D rose as APEX Phase 2 clinical trial expenses increased.",
      "importance": "medium",
      "evidence": "Research and development expense related to the zumilokibart program increased by $3.6 million in the three months ended June 30, 2026, compared to the three months ended June 30, 2025, primarily driven by an increase in clinical trial-related expenses associated with our APEX Phase 2 clinical trial.",
      "source_date": "2026-08-10"
    },
    {
      "type": "product_pipeline",
      "statement": "APG333/APG273 research expense declined as preclinical and clinical-trial expenses fell over the six-month comparison.",
      "importance": "medium",
      "evidence": "Research and development expense related to the APG333/APG273 program decreased by $3.0 million in the six months ended June 30, 2026, compared to the six months ended June 30, 2025, primarily due to a reduction in preclinical research and development expenses and clinical trial related expenses.",
      "source_date": "2026-08-10"
    },
    {
      "type": "demand",
      "statement": "Construction-materials revenue benefited from pricing and acquisitions, but asphalt volumes were lower after adverse weather.",
      "importance": "medium",
      "evidence": "For construction materials, revenues increased slightly primarily due to higher pricing and the contribution from recent acquisitions, partially offset by lower volumes in our asphalt business, which was impacted by adverse weather.",
      "source_date": "2026-08-05"
    }
  ],
  "related_tickers": [
    "ACA",
    "AGNCM",
    "APGE",
    "CRNX",
    "FANG",
    "FORTY",
    "GBTG",
    "HYG",
    "JNK",
    "SHY",
    "USO"
  ],
  "disclaimer": "Descriptive reporting of filed results. Not investment advice, and contains no forecast or recommendation."
}